Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important ...

For some cases of cancer, the starting point of a new treatment is already inside the patient. Cell therapy provides another option for advanced blood cancers that have not responded to other drugs.

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Engineers have developed a novel method for manufacturing CAR T cells, one that takes just 24 hours and requires only one step, thanks to the use of lipid nanoparticles (LNPs), the potent delivery ...

CLEVELAND and SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Cell X Technologies, pioneers in automated cell processing solutions, and Aspen Neuroscience, Inc., dedicated to autologous regenerative medicine, ...

In a new era of industrial revolution, intelligence is key. Knowing how product design can affect manufacturability or how production processes can affect finished quality helps manufacturers make ...